25 February 2021 - - The US-based National Comprehensive Cancer Network (NCCN) has updated their Clinical Practice Guidelines in Oncology (NCCN Guidelines) for B-Cell Lymphomas to include siltuximab (Sylvant) as the preferred primary treatment for patients with human immunodeficiency virus–negative [HIV(-)] and human herpesvirus 8–negative [HHV-8(-)] multicentric Castleman disease, also known as idiopathic multicentric Castleman disease, regardless of histopathologic subtype, UK-based biopharmaceutical company EUSA Pharma Ltd said.

Siltuximab is currently approved in more than 40 countries worldwide for the treatment of all histopathologic subtypes of iMCD, a rare, life-threatening and debilitating orphan condition of the lymph nodes and related tissues.

The update is based on a 2020 publication which demonstrated that there is insufficient evidence to guide treatment based solely on lymph node histopathologic subtype.

Siltuximab is a monoclonal antibody that directly neutralises IL-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions.

Sylvant (siltuximab) is currently approved by the US Food and Drug Administration and the European Commission, as well as regulatory authorities in several other jurisdictions worldwide, for the treatment of adult patients with multicentric Castleman disease who are human immunodeficiency virus negative and human herpesvirus-8 (HHV-8) negative.

Indications and Usage See EMA Summary of Product Characteristics and FDA Prescribing Information or additional information.

Founded in March 2015, EUSA Pharma is a biopharmaceutical company focused on oncology and rare disease.

The company is headquartered in Hemel Hempstead, England, and has extensive commercial operations in the United States and Europe, alongside a direct presence in selected other markets across the globe.